Truist Financial Corp Raises Stock Position in Genmab A/S (NASDAQ:GMAB)

Truist Financial Corp grew its stake in Genmab A/S (NASDAQ:GMAB – Get Rating) by 37.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 20,578 shares of the company’s stock after acquiring an additional 5,568 shares during the period. Truist Financial Corp’s holdings in Genmab A/S were worth $662,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the business. Wipfli Financial Advisors LLC purchased a new position in Genmab A/S during the 3rd quarter worth $171,000. Janney Montgomery Scott LLC raised its holdings in Genmab A/S by 8.0% in the third quarter. Janney Montgomery Scott LLC now owns 10,416 shares of the company’s stock valued at $335,000 after buying an additional 775 shares during the period. Legacy Wealth Asset Management LLC purchased a new stake in shares of Genmab A/S during the third quarter valued at approximately $514,000. Sawtooth Solutions LLC raised its stake in shares of Genmab A/S by 8.4% during the third quarter. Sawtooth Solutions LLC now owns 19,525 shares of the company’s stock valued at $627,000 after purchasing an additional 1,510 shares during the period. Finally, First Republic Investment Management Inc. increased its stake in shares of Genmab A/S by 22.9% in the second quarter. First Republic Investment Management Inc. now owns 73,746 shares of the company’s stock worth $2,396,000 after buying an additional 13,758 shares during the last quarter. 6.73% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $40.39 on Friday. Genmab A/S has a 52-week low of $26.19 and a 52-week high of $47.50. The company has a market capitalization of $26.64 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 1.18 and a beta of 1.02. The company has a 50-day simple moving average of $43.35 and a two-hundred day simple moving average of $38.58.

Genmab A/S (NASDAQ:GMAB – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.23 by $0.30. Genmab A/S had a net margin of 46.32% and a return on equity of 22.78%. The firm had revenue of $553.71 million during the quarter, compared to the consensus estimate of $486.10 million. On average, sell-side analysts forecast that Genmab A/S will post 1.39 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on GMAB shares. AlphaValue upgraded shares of Genmab A/S to a “reduce” rating in a research report on Thursday, November 17th. Deutsche Bank Aktiengesellschaft cut Genmab A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Citigroup cut Genmab A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 20th. JPMorgan Chase & Co. increased their price objective on Genmab A/S from 3,450.00 to 3,600.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 3rd. Finally, DNB Markets lowered Genmab A/S from a “buy” rating to a “hold” rating in a research report on Monday, October 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $632.12.

About Genmab A/S

(Get Rating)

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.